ABSTRACT
N-[2-(4'-methoxy[1,1'-biphenyl]-4-yl)ethyl]-8-CAC (1) is a high affinity (K(i)=0.084 nM) ligand for the µ opioid receptor and served as the lead compound for this study. Analogues of 1 were made in hopes of identifying an SAR within a series of oxygenated (distal) phenyl derivatives. A number of new analogues were made having single-digit pM affinity for the µ receptor. The most potent was the 3',4'-methylenedioxy analogue 18 (K(i)=1.6 pM).
Subject(s)
Cyclazocine/analogs & derivatives , Oxygen/chemistry , Receptors, Opioid, mu/agonists , Receptors, Opioid, mu/antagonists & inhibitors , Cyclazocine/chemical synthesis , Cyclazocine/chemistry , Cyclazocine/pharmacology , Dose-Response Relationship, Drug , Humans , Ligands , Molecular Structure , Structure-Activity RelationshipABSTRACT
A series of 7,8- and 8,9-fused triazole and imidazole analogues of cyclazocine have been made and characterized in opioid receptor binding and [(35)S]GTPgammaS assays. Target compounds were designed to explore the SAR surrounding our lead molecule for this study, namely the 8,9-fused pyrrolo analogue 2 of cyclazocine. Compared to 2, many of the new compounds in this study displayed very high affinity for opioid receptors.
Subject(s)
Cyclazocine/chemical synthesis , Cyclazocine/pharmacology , Receptors, Opioid/drug effects , Animals , CHO Cells , Cricetinae , Cricetulus , Cyclazocine/analogs & derivatives , Cyclazocine/metabolism , Cyclization , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Radioligand Assay , Receptors, Opioid/metabolism , Structure-Activity Relationship , Sulfur RadioisotopesABSTRACT
A series of 7,8- and 8,9-fused pyrimidinone, aminopyrimidine and pyridone derivatives of 8-carboxamidocyclazocine (8-CAC) have been prepared and evaluated in opioid receptor binding assays. Targets were designed to corroborate a pharmacophore hypothesis regarding the bioactive conformation of the carboxamide of 8-CAC. In addition to the results from this study strongly supporting this pharmacophore hypothesis, a number of novel compounds with high affinity to opioid receptors have been identified.
Subject(s)
Azocines/pharmacology , Cyclazocine/analogs & derivatives , Narcotic Antagonists , Receptors, Opioid/agonists , Animals , Azocines/chemical synthesis , Azocines/chemistry , Binding, Competitive/drug effects , CHO Cells , Cricetinae , Cricetulus , Cyclazocine/chemical synthesis , Cyclazocine/chemistry , Cyclazocine/pharmacology , Drug Design , Molecular Conformation , Stereoisomerism , Structure-Activity RelationshipABSTRACT
The synthesis and evaluation of a series of aryl-containing N-monosubstituted analogues of the lead compound 8-carboxamidocyclazocine were performed to probe a putative hydrophobic binding pocket of opioid receptors. High binding affinity to mu, kappa, and delta opioid receptors was observed for the 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogue.
Subject(s)
Cyclazocine/analogs & derivatives , Cyclazocine/chemical synthesis , Receptors, Opioid, delta/drug effects , Receptors, Opioid, kappa/drug effects , Receptors, Opioid, mu/drug effects , Animals , CHO Cells , Cricetinae , Cricetulus , Cyclazocine/pharmacology , Ethylketocyclazocine/analogs & derivatives , Ethylketocyclazocine/chemical synthesis , Ethylketocyclazocine/pharmacology , Humans , Hydrophobic and Hydrophilic Interactions , Radioligand Assay , Receptors, Opioid, delta/metabolism , Receptors, Opioid, kappa/metabolism , Receptors, Opioid, mu/metabolism , Stereoisomerism , Structure-Activity RelationshipABSTRACT
8-Position variants of cyclazocine have been made where the phenolic 8-OH was replaced by thioamide, amidine, guanidine, urea and thiourea groups. High affinity for opioid receptors was observed for the 8-CSNH2 and 8-NHCHS analogues indicating that these groups are isosteric with not only the 8-OH but with the previously synthesized 8-CONH2 and 8-NHCHO cyclazocine derivatives.
Subject(s)
Cyclazocine/chemistry , Cyclazocine/pharmacology , Structure-Activity RelationshipABSTRACT
The present study evaluated the effects of 8-carboxamidocyclazocine (8-CAC), a novel mixed-action kappa/mu agonist with a long duration of action, on food- and cocaine-maintained responding in rhesus monkeys to assess the potential utility of 8-CAC as a medication for the treatment of cocaine dependence. The effects of acute and chronic (10 days) 8-CAC were examined in rhesus monkeys responding under a multiple schedule for both cocaine and food reinforcement. Acute 8-CAC (0.032-0.56 mg/kg, i.m.) dose-dependently eliminated cocaine-maintained responding in all three monkeys. However, doses of 8-CAC that decreased cocaine self-administration typically also decreased food-maintained responding, and 8-CAC-induced decreases in cocaine self-administration diminished during chronic 8-CAC treatment. These results confirm that 8-CAC acutely decreases cocaine self-administration. However, non-selective effects of 8-CAC on food-maintained responding and tolerance to 8-CAC effects on cocaine self-administration may limit its potential for the treatment of cocaine dependence.
Subject(s)
Cocaine/pharmacology , Conditioning, Operant/drug effects , Cyclazocine/analogs & derivatives , Cyclazocine/pharmacology , Food , Receptors, Opioid, kappa/agonists , Receptors, Opioid, mu/agonists , Reward , Animals , Dose-Response Relationship, Drug , Female , Hypnotics and Sedatives/pharmacology , Macaca mulatta , Male , Reinforcement Schedule , Vomiting/chemically inducedABSTRACT
Kappa-opioid agonists produce neurobiological and behavioral effects opposite to those of cocaine and may be useful for the treatment of cocaine dependence. To evaluate the kappa- and mu-agonist effects of cyclazocine and to test whether cyclazocine pretreatment would attenuate the effects of cocaine, healthy, male and female, experienced opiate and cocaine users (n = 13) were enrolled in a two-phase study. In Phase 1, placebo, cyclazocine (0.2, 0.4 and 0.8 mg) and the mu-agonist hydromorphone (5 and 15 mg) were administered orally in six 4.5-hour sessions separated by at least 72 h. In Phase 2, cocaine (100 mg intranasal) was given 2 h after oral pretreatment with cyclazocine (0, 0.1, 0.2, 0.4, 0.8 and 0 mg, in that order) in each of six sessions conducted daily Monday to Friday and the following Monday. Physiological, subjective and behavioral measures were collected in each session. Nine participants completed Phase 1; eight completed Phase 2. Hydromorphone (15 mg) produced prototypic mu-agonist effects. Cyclazocine exhibited only modest kappa-like effects. Cyclazocine also had only modest, non-dose-related effects on response to cocaine. However, cocaine effects were consistently lower on the last administration (cyclazocine 0 mg pretreatment) following 4 days of cyclazocine pretreatment, compared to the first administration (0 mg pretreatment). This finding is unlikely to be fully attributable to cocaine tolerance and is not accounted for by pharmacokinetic changes; plasma concentrations of cocaine were not altered by cyclazocine. This study is suggestive but not strongly supportive for the use of kappa-opiate drugs to diminish acute effects of cocaine administration or for the use of these kappa agonists in drug abuse treatment applications.
Subject(s)
Cocaine/pharmacology , Cyclazocine/pharmacology , Hydromorphone/pharmacology , Receptors, Opioid, kappa/agonists , Receptors, Opioid, mu/agonists , Administration, Intranasal , Administration, Oral , Adult , Cocaine/administration & dosage , Cocaine-Related Disorders/drug therapy , Cyclazocine/therapeutic use , Drug Interactions , Female , Humans , Hydromorphone/therapeutic use , Male , Time FactorsABSTRACT
The cardiovascular effects of intravenous pentazocine and cyclazocine in dogs were studied under conscious, curarized-conscious (paralyzed by gallamine), and anesthetized states. In the conscious state, blood pressure and heart rate were dose-dependently increased by pentazocine (1, 2, 3 mg/kg) and to a lesser extent by cyclazocine (0.3 mg/kg). In all subsequent experiments on dogs, the results were obtained using 3 mg/kg pentazocine and 0.3 mg/kg cyclazocine. Pentazocine accelerated breathing, peaking at about 10 min, whereas cyclazocine reduced breathing to a minimum in 1 min, followed by a gradual recovery thereafter. In the curarized-conscious state, the blood pressure response to pentazocine was biphasic, namely an initial decrease followed by an increase; chronotrophic activity was stimulated. Pretreatment with either ganglionic or alpha andrenergic blocking agents not only significantly antagonized the pressory responses to the drug but also potentiated the initial decreases in blood pressure and unmasked a bradycardic component, but these parameters were not altered by 0.3 mg/kg naxalone. In open-chest anesthetized dogs, blood pressure, heart rate, contractility, and mean peripheral vascular resistance were simultaneously decreased by both pentazocine and cyclazocine, initially accompanied by increases in aortic blood flow. During the later stages of drug action, only the blood pressure and contractility were increased above control levels (biphasic effect). A comparison of blood pressure and heart rate responses to pentazocine in dogs kept under differing experimental conditions revealed that conscious dogs were more sensitive than curarized conscious and anesthetized animals to pentazocine action. In isolated guinea pig atria, the effect of adrenaline (0.1, 0.3, or 1 mg/mL) on the spontaneous breathing rate was significantly augmented by 10 mg/mL pentazocine (p < 0.02 for 0.3 g/mL; p < 0.01 for 0.1 g/mL adrenaline). In dogs, however, adrenaline (1 mg/kg)-induced increases in heart contractility, aortic blood flow, and blood pressure remained almost unaltered in the presence of pentazocine. We concluded that the abovementioned cardiovascular responses to pentazocine and cyclazocine are a consequence of the sum of the two following opposing effects: (i) an indirect reflex activation of sympathetic neuromediation in the periphery, and (ii) a direct membrane effect on the heart leading to bradycardia and a depression in myocardial contractility.
Subject(s)
Cardiovascular System/drug effects , Cyclazocine/pharmacology , Hemodynamics/drug effects , Pentazocine/pharmacology , Respiration/drug effects , Anesthesia , Animals , Blood Pressure/drug effects , Consciousness , Cyclazocine/administration & dosage , Dogs , Dose-Response Relationship, Drug , Female , Gallamine Triethiodide/pharmacology , Guinea Pigs , Heart Rate/drug effects , Injections, Intravenous , Male , Myocardial Contraction/drug effects , Pentazocine/administration & dosageABSTRACT
The adrenergic system plays a major role in the regulation of the uterine contractility during pregnancy. Our previous studies have shown the significance of the alpha1-adrenergic receptors (ARs) in the control of pregnant uterine contractility both in vitro and in vivo. Our present aim was to determine the changes in mRNA expression and pharmacological reactivity of the alpha1-ARs on days 18, 20, and 22 of pregnancy. To demonstrate the expressions of alpha1-AR subtype mRNA, we used a reverse transcription-polymerase chain reaction (RT-PCR); the pharmacological reactivity was tested by electric field stimulation (EFS). The expression of alpha1A-AR mRNA increased from day 18 to 22, while no alpha1B-AR mRNA was detectable. We found a small increase in the expression of alpha1D-AR mRNA on day 20, which was not followed by a significant change in pharmacological reactivity. The alpha1D-receptor expression and pharmacological reactivity decreased significantly up to day 22. EFS studies revealed that the alpha1A-AR antagonist 5-methylurapidil had EC50 values (1.9 x 10(-6)-6.3 x 10(-6) M) about one order of magnitude lower than those of the alpha1D-AR antagonist BMY 7378 (4 x 10(-6)-3.6 x 10(-5) M). However, the alpha1B-AR antagonist cyclazosine exerted only a slight effect on the stimulated contractions. Strong correlations were found between the alpha1A-mRNA expression and the EC50 of 5-methylurapidil (r(2) =0.9712), and between the alpha1D-AR mRNA expression and the EC50 of BMY 7378 (r(2) = 0.9937). Our findings suggest that both alpha1A- and alpha1D-ARs are involved in the regulation of the pregnant uterine contractility. The density and pharmacological reactivity indicate that the alpha(1A)-AR seems to play the major role in late-pregnant myometrial contraction.
Subject(s)
Myometrium/metabolism , Receptors, Adrenergic, alpha-1/genetics , Animals , Cyclazocine/pharmacology , Electric Stimulation Therapy , Female , Male , Myometrium/drug effects , Piperazines/pharmacology , Pregnancy , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, alpha-1/drug effects , Receptors, Adrenergic, alpha-1/metabolism , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
To obtain benzomorphans with a longer duration of action that may be potential therapeutics for treating cocaine abuse, 8-carboxamidocyclazocine was synthesized. The pharmacological properties of 8-carboxamidocyclazocine were compared with the parent compound cyclazocine. Changing the 8-hydroxyl group on cyclazocine to an 8-carboxamido group resulted in only a 2-fold decrease in the affinity of the compound for the kappa-receptor, and no change in the affinity for the mu-opioid receptor, with both compounds having K(i) values of less than 1 nM, based on radioligand binding assays. In the guanosine 5'-O -(3-[(35)S]thio)triphosphate ([(35)S]GTPgammaS) binding assay, the two compounds produced moderate stimulation of GTP binding to the human kappa- and mu-receptors. When given by i.c.v. injection, the compounds produced less than 60% antinociception in the mouse 55 degrees C warm-water tail-flick test. However, in the mouse writhing test, the compounds had high potency in producing antinociception. Antinociception induced by either 8-carboxamidocyclazocine or cyclazocine was mediated by both kappa- and mu-opioid receptors. Cyclazocine acted as a mu-antagonist in addition to its agonist properties at the mu-receptor, as measured by the inhibition of morphine-induced antinociception. In contrast, 8-carboxamidocyclazocine did not inhibit morphine-induced antinociception, demonstrating that it was not a mu-opioid receptor antagonist in this assay. An i.p. injection of an ED(70) dose of 8-carboxamidocyclazocine produced antinociception that lasted for 15 h in contrast to cyclazocine, which produced antinociception, lasting 2 h. 8-Carboxamidocyclazocine is a novel, long-acting benzomorphan, which possesses pharmacological properties that are distinct from the properties of cyclazocine.
Subject(s)
Cyclazocine/pharmacology , Receptors, Opioid, kappa/agonists , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology , Animals , Brain Chemistry/drug effects , Cyclazocine/analogs & derivatives , Cyclazocine/chemical synthesis , Dose-Response Relationship, Drug , GTP-Binding Proteins/metabolism , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Humans , Injections, Intraventricular , Male , Membranes/drug effects , Membranes/metabolism , Mice , Mice, Inbred ICR , Morphine/pharmacology , Narcotic Antagonists/pharmacology , Pain Measurement/drug effects , Receptors, Opioid, mu/drug effectsABSTRACT
(+)-cis-N-(4-Isothiocyanatobenzyl)-N-normetazocine (BNIT) (+)-(4) was designed and synthesized as a derivative of the potent and selective sigma(1) receptor ligand (+)-cis-N-benzyl-N-normetazocine for irreversibly blocking sigma(1) binding sites. Pretreatment of guinea pig brain membranes with BNIT (0.1, 1, and 5 microM) caused a concentration-dependent loss of binding of the selective sigma(1) ligand [(3)H]-(+)-pentazocine. Binding experiments with [(3)H]-1,3-di(2-tolyl)guanidine ([(3)H]-DTG), a ligand of sigma(1) and sigma(2) receptors, showed that pretreatment with BNIT blocked only the sigma(1) component of [(3)H]-DTG binding.
Subject(s)
Cyclazocine/analogs & derivatives , Cyclazocine/chemistry , Cyclazocine/chemical synthesis , Receptors, Opioid, delta/antagonists & inhibitors , Acylation , Animals , Binding Sites , Brain/metabolism , Cyclazocine/pharmacology , Guinea Pigs , In Vitro Techniques , Pentazocine/metabolism , Radioligand Assay , Receptors, Opioid, delta/metabolism , StereoisomerismABSTRACT
DL-Cyclazocine (0.5-2.0 mg/kg, i.p.) produced no impairment in rats' acquisition and retention of the behavior of swimming to a large visible platform in a water tank. However, cyclazocine produced a significant enhancement or potentiation of the impairment in swim-to-platform behavior produced by scopolamine. Since cyclazocine has previously been shown to abolish serotonin-dependent electrocortical activation (enabling it, in combination with central muscarinic blockade, to block all cortical activation), the results lend further support to the hypothesis that blockade of electrocortical activation produces dementia rather than sleep or coma as was previously believed.
Subject(s)
Cerebral Cortex/drug effects , Cyclazocine/pharmacology , Electroencephalography/drug effects , Learning/drug effects , Muscarinic Antagonists/pharmacology , Narcotic Antagonists/pharmacology , Scopolamine/pharmacology , Acetylcholine/metabolism , Afferent Pathways/drug effects , Afferent Pathways/metabolism , Animals , Arousal/drug effects , Arousal/physiology , Cerebral Cortex/metabolism , Dementia/chemically induced , Dementia/metabolism , Dementia/physiopathology , Dose-Response Relationship, Drug , Drug Interactions/physiology , Learning/physiology , Male , Rats , Rats, Long-Evans , Serotonin/metabolism , Swimming/physiology , Synaptic Transmission/drug effects , Synaptic Transmission/physiologyABSTRACT
In a previous study we found that substitutions of the (+)-cis-N-normetazocine nucleus of (+)-MPCB with 1-adamantanamine provide the compound (+/-)-10 with high affinity and selectivity for sigma receptors. Starting with this result we have synthesized a new series of eight 1-phenyl-2-cyclopropylmethylamines structurally related to (+/-)-10, and binding affinities, with respect to sigma 1, sigma 2, opioid and dopaminergic D2 receptors, have been reported. All compounds showed a negligible opioid and dopaminergic affinity and high selectivity for sigma receptors. Modifications on the amino moiety and methylcarboxyester group of 10 provide compounds with different sigma 1 and sigma 2 binding affinity and selectivity. Moreover, we have also synthesized the respective enantiomers of componds (+/-)-10 and (+/-)-18 in order to evaluate the enantioselectivity for sigma 1 and sigma 2 receptors. The binding data showed that carboxymethylester on the cyclopropane ring was more critical for enantioselectivity than the hydroxymethylenic group. In fact, the (-)-10 enantiomer showed a preference for sigma 1 whereas (+)-10 showed a preference for sigma 2.
Subject(s)
Analgesics, Opioid/chemical synthesis , Analgesics, Opioid/pharmacology , Cyclazocine/analogs & derivatives , Cyclazocine/chemical synthesis , Cyclazocine/pharmacology , Receptors, sigma/drug effects , Amino Acid Sequence , Humans , Ligands , Molecular Sequence Data , Receptors, Dopamine D2/drug effects , Stereoisomerism , Sigma-1 ReceptorABSTRACT
Recently, in an attempt to isolate the nonopioid sigma receptor, Su and colleagues purified a protein from rat liver and brain which appeared to resemble the original sigma opioid receptor as proposed by Martin in 1976, and for which the nonopiate sigma-1 ligand (+)pentazocine presents a high affinity. Previous in vivo electrophysiological studies from our laboratory have demonstrated that several selective sigma-1 ligands potentiate the neuronal response to NMDA. The goal of the present series of experiments was to assess the effects of some selective sigma-1 ligands on the potentiation of the NMDA response and to determine if this potentiation was mediated by the naloxone-sensitive sigma receptor. Extracellular unitary recordings from pyramidal neurons of the CA3 region of the rat dorsal hippocampus were obtained. The sigma-1 ligands BD 737, L 687-384, and JO-1784 (igmesine), administered intravenously at low doses, potentiated the NMDA response but the opiate antagonist naloxone failed to reverse this potentiation. However, the potentiation of the NMDA response induced by the sigma-1 ligand (+)pentazocine was suppressed by naloxone but not by the mu antagonist cyprodime hydrobomide, the kappa antagonist DIPPA nor by the delta antagonist naltrindole. (+/-) Cyclazocine, which presents a high affinity for the above-mentioned sigma-opiate receptor acted as an antagonist by suppressing the potentiation of the NMDA response induced by both JO-1784 and (+)pentazocine. These results suggest that the effects induced by some sigma-1 ligands may, in fact, be sensitive to naloxone while others may not. The original classification of sigma receptors as opiates might have been partly accurate.
Subject(s)
Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Pentazocine/pharmacology , Receptors, sigma/agonists , Action Potentials/drug effects , Animals , Cinnamates/administration & dosage , Cinnamates/pharmacology , Cyclazocine/administration & dosage , Cyclazocine/pharmacology , Cyclohexylamines/administration & dosage , Cyclohexylamines/pharmacology , Cyclopropanes/administration & dosage , Cyclopropanes/pharmacology , Excitatory Amino Acid Agonists/pharmacology , Injections, Intravenous , Male , N-Methylaspartate/pharmacology , Pentazocine/administration & dosage , Piperidines/administration & dosage , Piperidines/pharmacology , Pyramidal Cells/drug effects , Pyramidal Cells/physiology , Pyrrolidines/administration & dosage , Pyrrolidines/pharmacology , Rats , Rats, Sprague-DawleyABSTRACT
The interaction of the kappa-opioid receptor with arylacetamide and benzomorphan derivatives acting as agonists was modeled through pharmacophore-based and docking calculations. Potentially bioactive conformations of representative ligands (U-50,488 and its benzo-fused analogues 4 and 6 for arylacetamides and MPCB for benzomorphans) were identified by systematic conformational analysis and docked into a 3D model of the kappa-receptor. The obtained complexes, refined by energy-minimization and molecular dynamics, were evaluated for their consistency with structure-activity relationships and site-directed mutagenesis data. The following interactions are hypothesized to govern the ligand-receptor recognition process: (i) a salt bridge between the Asp138 carboxylate and the protonated nitrogen of the bound agonist; (ii) a hydrogen bond donated by the Tyr312 hydroxyl to the carbonyl oxygen of arylacetamides and MPCB; (iii) hydrophobic interactions established by the dichlorophenyl moiety of arylacetamides and the pendant phenyl ring of MPCB with the surrounding side chains of Tyr312, Leu224, Leu295, and Ala298; (iv) a pi-stacking contact between the Tyr312 side chain and the phenyl ring of arylacetamides; (v) a hydrogen bond linking the His291 imidazole ring to the phenolic hydroxy group featured by typical benzomorphans and the arylacetamides 4 and 6.
Subject(s)
Analgesics, Opioid/chemistry , Cyclazocine/analogs & derivatives , Receptors, Opioid, kappa/agonists , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/chemistry , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology , Analgesics, Non-Narcotic/chemistry , Analgesics, Non-Narcotic/pharmacology , Analgesics, Opioid/pharmacology , Computer Simulation , Cyclazocine/chemistry , Cyclazocine/pharmacology , Models, Chemical , Molecular Conformation , Receptors, Opioid, kappa/chemistry , Structure-Activity RelationshipABSTRACT
The relationship between the pharmacokinetics and the pharmacodynamics of eptazocine, a narcotic-antagonist analgesic, was investigated in rats. The analgesic effect of eptazocine (2.5, 5 and 10 mg/kg) following intravenous (i.v) administration was evaluated by both the Randall-Selitto method and the D'Amour-Smith method. The analgesic effects were determined before and at designed intervals for a period of 120 min after eptazocine administration, and are expressed as area under the effect-time curve (AUC(E)). The plasma concentration of eptazocine was determined by fluorescence HPLC and was analyzed with a two compartment open model using the nonlinear least-squares method. Eptazocine produced a dose-dependent analgesic effect. It was demonstrated that eptazocine has a linear relationship between AUC(E) and the area under the plasma concentration-time curve (AUC) following i.v. administration for three different doses ranging from 2.5 to 10 mg/kg.
Subject(s)
Analgesics/pharmacology , Analgesics/pharmacokinetics , Cyclazocine/analogs & derivatives , Cyclazocine/pharmacology , Cyclazocine/pharmacokinetics , Analgesics/blood , Animals , Area Under Curve , Cyclazocine/blood , Dose-Response Relationship, Drug , Female , Narcotic Antagonists/blood , Narcotic Antagonists/pharmacokinetics , Narcotic Antagonists/pharmacology , Nociceptors/drug effects , Pain Measurement/drug effects , Rats , Rats, WistarABSTRACT
(+/-)Cyclazocine, synthesized by Archer in 1962, was originally tested as a treatment for heroin addiction. (+/-)Cyclazocine is a mu opioid antagonist and kappa opioid agonist, and because of these actions, would be expected to modulate dopamine release in the nucleus accumbens as well as the reinforcing effects of drugs of abuse. In a recent study (+/-)cyclazocine was reported to decrease cocaine self-administration in rats. The aim of the present study was to determine whether (+/-)cyclazocine would alter the dopaminergic effects of nicotine that are thought to mediate its rewarding effects. Using in vivo microdialysis in awake and freely moving rats, we investigated the effect of (+/-)cyclazocine (0.5 mg/kg, i.p.) on the acute dopamine response to nicotine (0.32 mg/kg, i.v. over a 5 min period, infused 30 min later) in the nucleus accumbens. (+/-)Cyclazocine significantly attenuated the increase in extracellular dopamine levels induced by the nicotine infusion and enhanced nicotine-induced increases in dopamine metabolites. (+/-)Cyclazocine alone did not significantly affect extracellular dopamine levels. However, both the (+) and (-) enantiomers of cyclazocine did alter basal dopamine levels and these effects made it difficult to assess their individual interactions with nicotine. The results suggest that the effects of both enantiomers contribute to the effects of the racemate; (+/-)cyclazocine may decrease the rewarding effect of nicotine and may be the prototype of a potentially novel treatment for smoking.
Subject(s)
Cyclazocine/pharmacology , Dopamine/metabolism , Narcotic Antagonists/pharmacology , Nicotine/antagonists & inhibitors , Nicotinic Agonists/pharmacology , 3,4-Dihydroxyphenylacetic Acid/metabolism , Animals , Chromatography, High Pressure Liquid , Electrochemistry , Extracellular Space/drug effects , Extracellular Space/metabolism , Homovanillic Acid/metabolism , Male , Microdialysis , Nicotine/pharmacology , Rats , Rats, Sprague-Dawley , StereoisomerismABSTRACT
Cyclazocine is a kappa-opioid receptor agonist and mu-opioid receptor antagonist that was studied in the 1960s as a potential treatment for heroin addicts. Based on the evidence that opioid mechanisms modulate the reinforcing effects of cocaine, it has been suggested that cyclazocine be reconsidered for use in treating cocaine dependence. In the present study, the effects of orally administered (+/-)-cyclazocine, (+)-cyclazocine and (-)-cyclazocine on intravenous cocaine self-administration were assessed in rats. (+/-)-Cyclazocine produced a dose-related (2-8 mg/kg) decrease in cocaine intake without affecting bar-press responding for water. Neither enantiomer significantly altered responding for either cocaine or water. The efficacy of orally administered (+/-)-cyclazocine on cocaine self-administration was comparable to that previously observed using the intraperitoneal route. Distinct actions of the enantiomers of cyclazocine that might contribute to the unique efficacy of the racemate are discussed. Although the mechanistic basis for the results are not entirely understood, the data suggest that (+/-)-cyclazocine should be considered as a potential treatment for cocaine dependence.
Subject(s)
Cocaine/administration & dosage , Cyclazocine/pharmacology , Narcotic Antagonists/pharmacology , Administration, Oral , Animals , Cocaine-Related Disorders/drug therapy , Cyclazocine/therapeutic use , Female , Narcotic Antagonists/therapeutic use , Rats , Self Administration , Stereoisomerism , Structure-Activity RelationshipABSTRACT
Peritoneal irritation in rats induced by i.p. administration of acetic acid produces abdominal contractions reflecting visceral pain, and gastrointestinal ileus characterized by inhibition of gastric emptying and small intestine transit. In this study, gastric emptying (GE) and intestinal transit, calculated by the geometric center (GC) method, were estimated using a test meal labeled with 51Cr-EDTA. Visceral pain was assessed by counting abdominal contractions. Acetic acid produced abdominal contractions (80.8 +/- 3.3) and inhibition of GE (-54%) and GC (-63%) during the test-period. The kappa-opioid receptor agonists, CI-977 (+/-)-U-50,488H, (+/-)-bremazocine, PD-117,302, (-)-cyclazocine, and U-69,583, reversed abdominal contractions and inhibitions of gastrointestinal transit in a dose-related manner. The mu-opioid receptor agonists and potent analgesics, morphine and fentanyl did not restore normal gastric emptying and intestinal transit. These data suggest that selective kappa-opioid receptor agonists might be used to treat abdominal pain associated with motility and transit impairment during postoperative ileus.
Subject(s)
Analgesics/pharmacology , Intestinal Pseudo-Obstruction/drug therapy , Pain/drug therapy , Receptors, Opioid, kappa/agonists , 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer , Acetic Acid/toxicity , Animals , Benzofurans/pharmacology , Benzomorphans/pharmacology , Cyclazocine/pharmacology , Fentanyl/pharmacology , Gastric Emptying/drug effects , Intestinal Pseudo-Obstruction/etiology , Male , Morphine/pharmacology , Naloxone/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Pain/etiology , Peritoneum/drug effects , Pyrroles/pharmacology , Pyrrolidines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, mu/agonists , Thiophenes/pharmacologyABSTRACT
Recently synthesized compounds which have long-term mu antagonist activity and short-term kappa agonist effects prevent self-administration of cocaine and morphine in rats. Cyclazocine, a compound synthesized in 1962 and studied in animals and man in the 1960's and in the early 1970's is a mu antagonist in rats and man and is a potent kappa agonist in both species. It also prevents self-administration of cocaine and morphine in rats. Although it produces unpleasant side effects in man, subjects become tolerant to these side effects but not to the antagonistic actions of the drug after prolonged administration.